Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Regulatory News (GNS)

Share Price Information for Genus (GNS)

Share Price is delayed by 15 minutes
Get Live Data
2,178.00    -4.00 (-0.18%)
Bid:
2,192.00
Ask:
2,220.00
Spread: 28.00 (1.277%)
Market Cap: £1.45b
GNS Live PriceLast checked at - London Stock Exchange

Intraday Genus Share Chart

Interim Management Statement

11 May 2011 07:00

RNS Number : 3201G
Genus PLC
11 May 2011
 



For immediate release 11 May 2011

 

 

GENUS plc

("Genus" or "the Company")

 

Interim Management Statement

 

Genus, a leading global animal genetics company, today publishes its interim management statement for the period from 1 January 2011 to 10 May 2011.

Market Conditions

In general the markets in which the Group operates have continued to improve, despite continuing high feed costs.

Pig prices have kept pace with the increases in feed costs in most countries and, as a result, customer profitability and the demand for Genus' products have been sustained. The exception to this has been in Europe where price increases have not been sufficient to restore profitability for pig producers and so the market has been relatively soft. In China, prices started to increase following the disease outbreaks last year and this has led to improved demand for genetics.

In bovines, milk prices have risen to better levels in most markets.

Trading Performance

Based on the results for the four months to 30 April 2011, Genus has continued to perform ahead of last year and in line with the Board's expectations.

In North America, the porcine business has continued to trade well with increased royalty income. In bovine, improved average selling prices and the benefit of cost reductions implemented in the first half of the year have improved profitability on sales at a similar level to last year. Demand has remained buoyant in Latin America resulting in increased volumes in both the bovine and porcine sectors.

In Europe, bovine performance improved as sales delayed from the first half of the year came through and dairy markets firmed. Porcine performance remained weak with reduced customer demand because of poor industry profitability.

In the Far East, strong growth in bovine volumes continued. Porcine performance began to improve as customer demand in China increased following a rise in pig prices.

Good progress has continued with the initiatives aimed at ensuring emerging market growth opportunities. Work to bring the new stud in Russia up to Genus' standards is nearing completion. A further 16 bulls have been shipped to China to meet the growing demand for progeny tested semen and strong sales growth is being achieved in India.

Financial Position

Net debt at 30 April 2011 of £85.4m was below the level at the same time last year (£94.0m), reflecting the group's underlying strong cash generation. It was, however, higher than at 31 December 2010, mainly because of the payment of the annual dividend and the £7.0m cash settlement cost of a US dollar swap transaction used to hedge the Group's US dollar net asset position.

The Group completed a refinancing in March 2011 to provide £135m of facilities on an unsecured basis through to 30 September 2015.

Outlook

Genus expects to continue to make good progress for the remainder of the year and that, as a result, the full year results to June 2011 will be in line with the Board's expectations.

Genus will announce its preliminary results for the year ending 30 June 2011 on 6 September 2011.

 

For further information please contact:-

 

Genus plc Tel: 01256 345970

 

Richard Wood, Chief Executive

John Worby, Finance Director

 

Buchanan Communications Tel: 0207 466 5000

 

Charles Ryland

Suzanne Brocks

Helen Chan

 

This announcement is available on the Genus website, www.genusplc.com

 

 

 

 

About Genus:

 

Genus plays a key role in the world's agricultural economy in its creation of advances in animal breeding through naturally applied biotechnology, helping farmers and food producers across the world to improve quality and increase output.

 

Genus provides superior natural animal genetics, enabling our global customers in the bovine and porcine supply chain to produce offspring in their herds with greater production efficiency, milk and meat output and quality. The challenge of meeting growing global demand for milk, pork and beef from the decreasing resources available for food production requires innovative solutions that Genus provides.

 

Genus' worldwide sales are made in seventy countries under the trade marks "ABS" (dairy and beef cattle) and "PIC" (pigs) and comprise semen and breeding animals with superior genetics to those animals currently in production.

 

Genus' competitive edge has been created from the ownership and control of proprietary lines of breeding animals and the biotechnology used to improve them. Genus' global production and distribution network underpins our unique position in the world's growing agricultural markets.

 

Headquartered in Basingstoke, England, Genus is a FTSE250 company that operates in 30 countries on six continents, with research laboratories located in Madison, Wisconsin, USA.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSSFAFLSFFSELI
Date   Source Headline
2nd Oct 20135:00 pmRNSTotal Voting Rights
27th Sep 20136:19 pmRNSDirector/PDMR Shareholding
23rd Sep 20137:00 amRNSGenus to Acquire Génétiporc
3rd Sep 20133:04 pmRNSCorrection of Record Date
3rd Sep 20137:00 amRNSPreliminary Results
31st Jul 20133:00 pmRNSBlocklisting Interim Review
25th Jul 201310:14 amRNSCompany Secretary Appointment
18th Jul 20139:00 amRNSHolding(s) in Company
11th Jun 20135:07 pmRNSHolding(s) in Company
4th Jun 20139:10 amRNSHolding(s) in Company
31st May 20132:00 pmRNSTotal Voting Rights
23rd May 20138:22 amRNSDirector/PDMR Shareholding
21st May 20134:56 pmRNSHolding(s) in Company
30th Apr 20137:00 amRNSInterim Management Statement
8th Apr 20136:09 pmRNSHolding(s) in Company
8th Apr 201310:27 amRNSHolding(s) in Company
28th Mar 20134:13 pmRNSHolding(s) in Company
28th Mar 20133:51 pmRNSTotal Voting Rights
21st Mar 20132:00 pmRNSHolding(s) in Company
11th Mar 20134:07 pmRNSDirector/PDMR Shareholding
4th Mar 20132:00 pmRNSHolding(s) in Company
28th Feb 20132:30 pmRNSTotal Voting Rights
28th Feb 20132:00 pmRNSDirector/PDMR Shareholding
25th Feb 20134:21 pmRNSDirector/PDMR Shareholding
25th Feb 20137:00 amRNSInterim Results
25th Feb 20137:00 amRNSSecond New Joint Venture in China
4th Feb 201310:00 amRNSHolding(s) in Company
31st Jan 20132:00 pmRNSBlocklisting Interim Review
31st Jan 20132:00 pmRNSTotal Voting Rights
8th Jan 20132:00 pmRNSHolding(s) in Company
13th Dec 20127:00 amRNSDirectorate Change
7th Dec 201210:00 amRNSDirector/PDMR Shareholding
30th Nov 20122:00 pmRNSTotal Voting Rights
14th Nov 201210:00 amRNSHolding(s) in Company
8th Nov 20123:30 pmRNSAGM Statement
8th Nov 20127:00 amRNSAGM and Interim Management Statement
31st Oct 20122:03 pmRNSTotal Voting Rights
26th Oct 201210:00 amRNSHolding(s) in Company
17th Oct 201210:00 amRNSHolding(s) in Company
9th Oct 20122:00 pmRNSAnnual Report and details of AGM
28th Sep 20122:00 pmRNSTotal Voting Rights
27th Sep 201211:00 amRNSAdditional Listing
27th Sep 20128:00 amRNSHolding(s) in Company
26th Sep 20124:01 pmRNSDirector/PDMR Shareholding
4th Sep 20127:00 amRNSPreliminary Results
31st Aug 20122:00 pmRNSTotal Voting Rights
23rd Aug 20126:18 pmRNSHolding(s) in Company
20th Aug 20127:00 amRNSAppointment of Joint Broker
31st Jul 20122:00 pmRNSBlocklisting Interim Review
31st Jul 20122:00 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.